This additional analysis is presented for observation only. It is unknown if the following results were due to FABHALTA. We cannot make conclusions from these data, but they are useful to help guide future research.

Percentage of people who maintained Hb levels of ≥12 g/dL between Weeks 18 and 24 without a need for red blood cell (RBC) transfusions

• The average Hb level at the start of the study was 8.2 g/dL, which is below normal Hb levels

• Normal Hb levels vary but are generally between 12-16 g/dL for women and 13-18 g/dL for men

78% of people on FABHALTA (31 of 40) reached Hb levels of ≥12 g/dL* without a need for RBC transfusions between Weeks 2 and 48.

This additional analysis is presented for observation only. It is unknown if the following results were due to FABHALTA. We cannot make conclusions from these data, but they are useful to help guide future research.

Percentage of people who didn’t need RBC transfusions between Weeks 2 and 24

In the 6 months before starting this study, 70% of people (28 of 40) needed RBC transfusions.

98% of people on FABHALTA (39 of 40) did not need RBC transfusions between Weeks 2 and 48.

Before the study began and at various points during the study, people rated their fatigue using the FACIT-Fatigue scale, a 13-item questionnaire used to measure fatigue and its impact on daily activities and function.

FACIT-Fatigue scores range from 0 to 52

*The average FACIT (Functional Assessment of Chronic Illness Therapy)-Fatigue score for the general population was determined in a study of 1010 adults in the United States in 2002 and 2426 adults in Germany in 2018.

Fatigue was studied with FABHALTA

Data from this analysis describe how people reported their fatigue.
There are important limitations to the data presented below that you should consider:

• Because people in the trial knew they were on FABHALTA, they may have under- or over-estimated their fatigue

• Because of the small number of people in the trial (40) and the fact that people knew the medicine they were taking, it is unknown if these results were due to FABHALTA and no conclusions can be made about the effect of FABHALTA on fatigue

Average change in FACIT-Fatigue score at 24 weeks^† compared to the start of the study

Average change in FACIT-Fatigue score at Week 48 compared to the start of the study

• +10.9 points for people who continued taking FABHALTA (39 of 40)

^†FACIT-Fatigue score was assessed between Weeks 18 and 24.